$CYCN
Cyclerion Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021966 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $608.0K $0.00 $348.0K
YoY Change 14.07% -100.0% -13.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.506M $3.525M $4.601M
YoY Change -20.55% -23.39% -42.7%
% of Gross Profit
Research & Development $4.450M $7.082M $7.032M
YoY Change -57.45% 0.71% -48.68%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $48.00K
YoY Change -100.0% -100.0% -91.86%
% of Gross Profit
Operating Expenses $7.956M $10.61M $11.63M
YoY Change -46.5% -8.82% -47.55%
Operating Profit -$10.61M -$11.29M
YoY Change -6.01% -48.19%
Interest Expense $132.0K $111.0K -$5.000K
YoY Change -13300.0% -2320.0% -105.56%
% of Operating Profit
Other Income/Expense, Net $111.0K -$5.000K
YoY Change -2320.0% -105.38%
Pretax Income -$7.216M -$10.50M -$11.29M
YoY Change -33.03% -7.03% -39.98%
Income Tax
% Of Pretax Income
Net Earnings -$7.216M -$10.50M -$11.29M
YoY Change -33.03% -7.03% -39.99%
Net Earnings / Revenue -1186.84% -3244.25%
Basic Earnings Per Share -$0.24 -$0.26
Diluted Earnings Per Share -$0.17 -$0.24 -$260.8K
COMMON SHARES
Basic Shares Outstanding 43.49M 43.49M 43.29M
Diluted Shares Outstanding 43.49M 43.29M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.38M $20.41M $62.50M
YoY Change -75.2% -67.35% -6.43%
Cash & Equivalents $13.38M $20.41M $62.50M
Short-Term Investments
Other Short-Term Assets $537.0K $488.0K $459.0K
YoY Change 14.74% 6.32% -72.45%
Inventory
Prepaid Expenses $805.0K $536.0K $562.0K
Receivables $96.00K $227.0K $158.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $14.82M $21.66M $63.68M
YoY Change -73.28% -65.99% -9.19%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $112.0K
YoY Change -100.0% -100.0% -98.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.041M $2.133M $2.499M
YoY Change -15.21% -14.65% -12.77%
Total Long-Term Assets $3.259M $3.397M $4.060M
YoY Change -15.88% -16.33% -93.37%
TOTAL ASSETS
Total Short-Term Assets $14.82M $21.66M $63.68M
Total Long-Term Assets $3.259M $3.397M $4.060M
Total Assets $18.08M $25.05M $67.74M
YoY Change -69.53% -63.02% -48.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.970M $1.645M $1.174M
YoY Change 62.47% 40.12% -13.68%
Accrued Expenses $4.589M $6.725M $5.839M
YoY Change -47.61% 15.17% -44.92%
Deferred Revenue
YoY Change
Short-Term Debt $3.500M $0.00 $3.509M
YoY Change 0.0% -100.0% 0.26%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.627M $8.529M $11.36M
YoY Change -31.2% -24.89% -30.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.627M $8.529M $11.36M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $7.627M $8.529M $11.36M
YoY Change -31.2% -24.89% -79.72%
SHAREHOLDERS EQUITY
Retained Earnings -$259.2M -$251.9M -$204.3M
YoY Change 20.52% 23.32% 41.68%
Common Stock $269.6M $268.5M $260.7M
YoY Change 2.39% 2.98% 18.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.45M $16.52M $56.39M
YoY Change
Total Liabilities & Shareholders Equity $18.08M $25.05M $67.74M
YoY Change -69.53% -63.02% -48.45%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$7.216M -$10.50M -$11.29M
YoY Change -33.03% -7.03% -39.99%
Depreciation, Depletion And Amortization $0.00 $0.00 $48.00K
YoY Change -100.0% -100.0% -91.86%
Cash From Operating Activities -$7.043M -$9.915M -$7.923M
YoY Change -18.39% 25.14% -47.36%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$7.000K
YoY Change -100.0% -30.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 -$7.000K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.00K 0.000 43.00K
YoY Change -85.88% -100.0% -99.82%
NET CHANGE
Cash From Operating Activities -7.043M -9.915M -7.923M
Cash From Investing Activities 0.000 0.000 -7.000K
Cash From Financing Activities 12.00K 0.000 43.00K
Net Change In Cash -7.031M -9.915M -7.887M
YoY Change -17.72% 25.71% -185.54%
FREE CASH FLOW
Cash From Operating Activities -$7.043M -$9.915M -$7.923M
Capital Expenditures $0.00 $0.00 -$7.000K
Free Cash Flow -$7.043M -$9.915M -$7.916M
YoY Change -18.39% 25.25% -47.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2133000
dei Amendment Flag
AmendmentFlag
false
cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
138000
dei Entity Central Index Key
EntityCentralIndexKey
0001755237
us-gaap Depreciation And Amortization
DepreciationAndAmortization
65000
us-gaap Defined Contribution Plan Type Extensible List
DefinedContributionPlanTypeExtensibleList
http://fasb.org/us-gaap/2022#QualifiedPlanMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Depreciation And Amortization
DepreciationAndAmortization
424000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2407000
CY2022Q3 us-gaap Assets
Assets
25053000
CY2021Q4 us-gaap Assets
Assets
59331000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1645000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
2904000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8529000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11085000
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43494184
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43494184
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43410185
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43410185
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251938000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215076000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
268490000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
263345000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16524000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48246000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25053000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59331000
CY2022Q3 cycn Revenue From License
RevenueFromLicense
0
CY2021Q3 cycn Revenue From License
RevenueFromLicense
0
cycn Revenue From License
RevenueFromLicense
0
CY2022Q3 cycn Revenue From Grant
RevenueFromGrant
0
CY2021Q3 cycn Revenue From Grant
RevenueFromGrant
271000
cycn Revenue From Grant
RevenueFromGrant
720000
cycn Revenue From Grant
RevenueFromGrant
271000
CY2022Q3 us-gaap Revenues
Revenues
0
CY2021Q3 us-gaap Revenues
Revenues
348000
us-gaap Revenues
Revenues
1017000
us-gaap Revenues
Revenues
3409000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7082000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7032000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27043000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27178000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3525000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4601000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10998000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16207000
CY2022Q3 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
CY2021Q3 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-881000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
10607000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
11633000
us-gaap Operating Expenses
OperatingExpenses
38041000
us-gaap Operating Expenses
OperatingExpenses
44266000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10607000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11285000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37024000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40857000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
111000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
162000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10496000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11290000
us-gaap Net Income Loss
NetIncomeLoss
-36862000
us-gaap Net Income Loss
NetIncomeLoss
-40872000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43488000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43488000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43291000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43291000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43457000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43457000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37730000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37730000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10496000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11290000
us-gaap Net Income Loss
NetIncomeLoss
-36862000
us-gaap Net Income Loss
NetIncomeLoss
-40872000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10499000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-11290000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-36867000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-40871000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
59493000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13399000
CY2021Q1 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
27000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1921000
CY2021Q1 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
391000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
48433000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16182000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30497000
CY2021Q2 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
133000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1942000
CY2021Q2 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
398000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
65222000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11290000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6000
CY2021Q3 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
37000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2018000
CY2021Q3 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
394000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
56387000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48246000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12978000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1476000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37034000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13388000
CY2022Q2 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
17000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1410000
CY2022Q2 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
289000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25361000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10496000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1372000
CY2022Q3 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
290000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16524000
us-gaap Profit Loss
ProfitLoss
-36862000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6322000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-881000
us-gaap Share Based Compensation
ShareBasedCompensation
5128000
us-gaap Share Based Compensation
ShareBasedCompensation
7064000
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
127000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
158000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
0
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-127000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-392000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-254000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
20000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1254000
cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-138000
cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
105000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-274000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-274000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-183000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
25000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
0
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-286000
cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-2037000
cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
2011000
cycn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
0
cycn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1048000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-336000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4054000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33568000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27887000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1464000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1457000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
30503000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
17000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
197000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30700000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33556000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4271000
dei Entity File Number
EntityFileNumber
001-38787
dei Entity Registrant Name
EntityRegistrantName
CYCLERION THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1895370
dei Entity Address Address Line1
EntityAddressAddressLine1
245 First Street, 18th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53961000
dei Local Phone Number
LocalPhoneNumber
327-8778
dei Security12b Title
Security12bTitle
Common Stock, no par value
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58232000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20405000
dei Trading Symbol
TradingSymbol
CYCN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62503000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20405000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62503000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62503000
CY2020Q3 cycn Rentable Square Feet Terminated From Lease Agreement
RentableSquareFeetTerminatedFromLeaseAgreement
15700
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2022Q3 cycn Sublease Termination Agreement Estimated Fair Value Of Rooms
SubleaseTerminationAgreementEstimatedFairValueOfRooms
1500000
CY2022Q3 cycn Sublease Termination Agreement Estimated Fair Value Of Services
SubleaseTerminationAgreementEstimatedFairValueOfServices
2900000
cycn Prepaid Rooms Balance Related To Other Assets
PrepaidRoomsBalanceRelatedToOtherAssets
1400000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P8Y10M17D
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43457000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43457000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37730000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37730000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43494184
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20405000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53961000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
227000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
100000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
536000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
928000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
488000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
468000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
21656000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
55457000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Payments To Employees
PaymentsToEmployees
10000000
cycn Tax Credit To Employee
TaxCreditToEmployee
7000000
cycn Payroll Costs Offset
PayrollCostsOffset
200000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1264000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1402000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1828000
CY2022Q3 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4316000
CY2021Q4 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6353000
CY2022Q3 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
2568000
cycn Revenue From License
RevenueFromLicense
3000000
CY2022Q3 cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
0
CY2021Q3 cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
77000
cycn Revenue From Development Agreement
RevenueFromDevelopmentAgreement
297000
CY2022Q2 cycn Threshold Consecutive Business Days For Which Notice Received From Nasdaq For Not Maintaining The Minimum Bid Price
ThresholdConsecutiveBusinessDaysForWhichNoticeReceivedFromNasdaqForNotMaintainingTheMinimumBidPrice
30
CY2022Q2 cycn Minimum Bid Price Of Its Common Stock
MinimumBidPriceOfItsCommonStock
1.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q1 cycn Sharebased Compensation Expense Related To Issuance Of Stock Options To Non Employees
SharebasedCompensationExpenseRelatedToIssuanceOfStockOptionsToNonEmployees
291000
us-gaap Profit Loss
ProfitLoss
-40872000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20405000
cycn Health Care Trust Amount Description
HealthCareTrustAmountDescription
We recently capped enrollment in our signal-seeking clinical study of CY6463 for the potential treatment of Alzheimer's disease with vascular pathology ("ADv"), which will enable the Company to channel its resources to its most urgent priorities in MELAS. Data from the ADv study is expected in the first half of 2023. Learnings from this and previous CY6463 studies can be leveraged to optimize future potential Alzheimer's Disease/Vascular Dementia studies. The ADv study is supported in part by a $2 million grant from the Alzheimer’s Association’s Part the Cloud-Gates Partnership Grant Program (the "PTC Grant")
cycn Common Stock Issued Or Sold Under The Atm Offering
CommonStockIssuedOrSoldUnderTheAtmOffering
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles ("GAAP") requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments, and methodologies. Significant estimates and assumptions in the consolidated financial statements include those related to revenue, impairment of long-lived assets, valuation procedures for right-of-use ("ROU") assets and operating lease liabilities, income taxes, including the valuation allowance for deferred tax assets, research and development expenses, contingencies, share-based compensation and going concern. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assumptions </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2265000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2265000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2265000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2200000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65000
CY2022Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1017000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1369000
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
383000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
266000
CY2022Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
330000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
345000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
679000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
398000
CY2022Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
159000
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
526000
CY2022Q3 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
2568000
CY2021Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
2904000
CY2021Q3 us-gaap Lease Cost
LeaseCost
600000
us-gaap Lease Cost
LeaseCost
2200000
us-gaap Lease Cost
LeaseCost
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1662000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2412000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5128000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7064000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
37686
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
375000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.01
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y5M8D
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10496000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11290000
us-gaap Net Income Loss
NetIncomeLoss
-36862000
us-gaap Net Income Loss
NetIncomeLoss
-40872000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43488000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43488000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43291000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43291000
CY2022Q3 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
8204113000
CY2021Q3 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
7113789000
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
8204113000
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
7113789000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.75
cycn Defined Contribution Plan Employer Matching Contribution Maximum
DefinedContributionPlanEmployerMatchingContributionMaximum
6000
CY2022Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2021Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
cycn Ptc Grant Award
PtcGrantAward
2000000
CY2022Q3 cycn Allowable Expenses On Grant Revenue
AllowableExpensesOnGrantRevenue
0
cycn Allowable Expenses On Grant Revenue
AllowableExpensesOnGrantRevenue
700000

Files In Submission

Name View Source Status
cycn-20220930_cal.xml Edgar Link unprocessable
0000950170-22-021966-index-headers.html Edgar Link pending
0000950170-22-021966-index.html Edgar Link pending
0000950170-22-021966.txt Edgar Link pending
0000950170-22-021966-xbrl.zip Edgar Link pending
cycn-20220930.htm Edgar Link pending
cycn-20220930.xsd Edgar Link pending
cycn-ex31_1.htm Edgar Link pending
cycn-ex31_2.htm Edgar Link pending
cycn-ex32_1.htm Edgar Link pending
cycn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
cycn-20220930_def.xml Edgar Link unprocessable
cycn-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cycn-20220930_htm.xml Edgar Link completed
cycn-20220930_pre.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending